Mutations of the VHL tumour suppressor gene in renal carcinoma
The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
This immunotherapeutic approach can result in marked tumor regression in some patients for whom no other effective therapy is available at present, and determining its ultimate role in cancer therapy awaits further attempts to increase the therapeutic efficacy of treatment and decrease its toxicity and complexity.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival.
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
Among men undergoing biopsy for suspected prostate cancer, targeted MR/ultrasound fusionBiopsy, compared with standard extended-sextant ultrasound-guided biopsy, was associated with increased detection of high-risk prostate cancer and decreased detection of low- risk prostate cancer.
The Molecular Taxonomy of Primary Prostate Cancer
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
- J. Herman, F. Latif, W. Linehan
- BiologyProceedings of the National Academy of Sciences…
- 11 October 1994
The findings suggest that aberrant methylation of CpG islands may participate in the tumor-suppressor gene inactivations which initiate or cause progression of common human cancers.
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Nonmyeloablative allogeneic stem-cell transplantation can induce sustained regression of metastatic renal-cell carcinoma in patients who have had no response to conventional immunotherapy, consistent with a graft-versus-tumor effect.
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
The present study shows that mutations in FH are associated with HLRCC in North America, and expands the histologic spectrum of renal tumors and FH mutations associated withHLRCC.
Reductive carboxylation supports growth in tumor cells with defective mitochondria
These findings reveal the novel induction of a versatile glutamine-dependent pathway that reverses many of the reactions of the canonical CAC, supports tumour cell growth, and explains how cells generate pools of CAC intermediates in the face of impaired mitochondrial metabolism.